MX2019011911A - Procesos e compuestos intermedios en la preparacion de antagonistas de c5ar. - Google Patents
Procesos e compuestos intermedios en la preparacion de antagonistas de c5ar.Info
- Publication number
- MX2019011911A MX2019011911A MX2019011911A MX2019011911A MX2019011911A MX 2019011911 A MX2019011911 A MX 2019011911A MX 2019011911 A MX2019011911 A MX 2019011911A MX 2019011911 A MX2019011911 A MX 2019011911A MX 2019011911 A MX2019011911 A MX 2019011911A
- Authority
- MX
- Mexico
- Prior art keywords
- intermediates
- preparation
- processes
- c5ar antagonists
- c5ar
- Prior art date
Links
- 239000000543 intermediate Substances 0.000 title abstract 2
- 102100032957 C5a anaphylatoxin chemotactic receptor 1 Human genes 0.000 title 1
- 101710098483 C5a anaphylatoxin chemotactic receptor 1 Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 229940126681 complement 5a receptor antagonist Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se proporcionan intermediarios y métodos para la preparación de compuestos antagonistas de C5aR seleccionados.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462057107P | 2014-09-29 | 2014-09-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019011911A true MX2019011911A (es) | 2019-11-25 |
Family
ID=55583729
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017003789A MX368492B (es) | 2014-09-29 | 2015-09-28 | Procesos e compuestos intermedios en la preparacion de antagonistas de c5ar. |
MX2019011911A MX2019011911A (es) | 2014-09-29 | 2017-03-23 | Procesos e compuestos intermedios en la preparacion de antagonistas de c5ar. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017003789A MX368492B (es) | 2014-09-29 | 2015-09-28 | Procesos e compuestos intermedios en la preparacion de antagonistas de c5ar. |
Country Status (19)
Country | Link |
---|---|
US (5) | US9745268B2 (es) |
EP (2) | EP3200791B1 (es) |
JP (1) | JP6898229B6 (es) |
KR (2) | KR20230149873A (es) |
CN (2) | CN113121415A (es) |
AU (2) | AU2015324111B2 (es) |
BR (1) | BR112017006232B1 (es) |
CA (2) | CA3220371A1 (es) |
DK (1) | DK3200791T3 (es) |
ES (2) | ES2926828T3 (es) |
IL (1) | IL251061B (es) |
MA (1) | MA52308A (es) |
MX (2) | MX368492B (es) |
NZ (2) | NZ730123A (es) |
PL (1) | PL3200791T3 (es) |
PT (1) | PT3200791T (es) |
RU (1) | RU2712233C2 (es) |
SG (1) | SG11201702185UA (es) |
WO (1) | WO2016053890A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG172338A1 (en) | 2008-12-22 | 2011-07-28 | Chemocentryx Inc | C5ar antagonists |
SI2585064T1 (sl) | 2010-06-24 | 2017-08-31 | Chemocentryx, Inc. | Antagonisti C5AR |
ES2926828T3 (es) * | 2014-09-29 | 2022-10-28 | Chemocentryx Inc | Procesos e intermedios en la preparación de antagonistas de C5aR |
US20170202821A1 (en) | 2016-01-14 | 2017-07-20 | Chemocentryx, Inc. | Method of treating c3 glomerulopathy |
EP3703687A4 (en) * | 2017-10-30 | 2021-04-07 | ChemoCentryx, Inc. | DEUTERATED COMPOUNDS USED AS IMMUNOMODULATORS |
EP3801519A4 (en) | 2018-06-07 | 2022-03-30 | ChemoCentryx, Inc. | DOSAGE AND EFFECT OF A C5A ANTAGONIST IN ANCA-ASSOCIATED VASCULITIS |
MA54318B1 (fr) | 2018-11-30 | 2023-08-31 | Chemocentryx Inc | Formulations de capsules |
KR102207333B1 (ko) * | 2019-09-09 | 2021-01-27 | 성균관대학교산학협력단 | 4중 연속 고리 화합물의 신규한 제조방법 |
BR112022007489A2 (pt) | 2019-11-08 | 2022-07-12 | Chemocentryx Inc | Forma amorfa de um receptor c5a de componente do complemento |
KR20220098179A (ko) * | 2019-11-08 | 2022-07-11 | 케모센트릭스, 인크. | 보체 성분 C5a 수용체의 유리 염기 결정질 형태 |
TW202128623A (zh) | 2019-11-08 | 2021-08-01 | 美商卡默森屈有限公司 | 補體成分C5a受體之鹽形式 |
WO2022078269A1 (zh) * | 2020-10-16 | 2022-04-21 | 苏州科睿思制药有限公司 | Avacopan的晶型及其制备方法和用途 |
WO2022263263A1 (en) | 2021-06-16 | 2022-12-22 | Sandoz Ag | Crystalline form of avacopan |
EP4137133A1 (en) | 2021-08-19 | 2023-02-22 | Sandoz AG | Crystalline form of avacopan |
CN113957106B (zh) * | 2021-11-03 | 2024-04-19 | 暨明医药科技(苏州)有限公司 | 一种Avacopan及其中间体的制备方法 |
CN114262291B (zh) * | 2022-01-04 | 2023-05-19 | 重庆医科大学 | 一种阿伐可泮的合成方法 |
WO2023158722A2 (en) | 2022-02-16 | 2023-08-24 | Teva Pharmaceuticals International Gmbh | Processes for preparation of avacopan and intermediates thereof |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4686100A (en) | 1985-04-02 | 1987-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Method for the treatment of adult respiratory distress syndrome |
CN1261098C (zh) | 1998-08-28 | 2006-06-28 | 西奥斯股份有限公司 | p38-α激酶的抑制剂 |
RU2197288C2 (ru) | 1999-08-03 | 2003-01-27 | Тверская медицинская академия | Способ лечения больных хроническим гломерулонефритом |
US6713502B2 (en) | 2000-05-05 | 2004-03-30 | Smithkline Beecham Corporation | Anti-infectives |
NZ523444A (en) * | 2000-06-29 | 2004-12-24 | Abbott Lab | Aryl phenylcyclopropyl sulphide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents |
EP1308438B9 (en) | 2000-08-10 | 2012-03-28 | Mitsubishi Tanabe Pharma Corporation | 3-substituted urea derivatives and medicinal use thereof |
CN102050758A (zh) | 2000-09-14 | 2011-05-11 | 田边三菱制药株式会社 | 酰胺衍生物及其制备药物的用途 |
AU7622500A (en) | 2000-09-29 | 2002-07-01 | Neurogen Corp | High affinity small molecule c5a receptor modulators |
SE524438C2 (sv) | 2000-10-05 | 2004-08-10 | Magnus Georg Goertz | Fjärrstyrt dörrelaterat låsarrangemang, första och andra datorpogramprodukt, bärande medium och ett datorlösbart medium |
DE10293171D2 (de) | 2001-07-19 | 2004-07-01 | Luk Lamellen & Kupplungsbau | Ausrücksystem zur Betätigung einer Kupplung eines Fahrzeuges |
ES2283594T5 (es) | 2001-08-17 | 2016-03-15 | Genentech, Inc. | Inhibidores de la ruta del complemento que se unen a C5 y C5a sin impedir la formación de C5b |
MXPA04002662A (es) | 2001-09-21 | 2004-11-22 | Sanofi Aventis | Derivados de 3-substituida-4-pirimidona. |
ITMI20012025A1 (it) | 2001-09-28 | 2003-03-28 | Dompe Spa | Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono |
US20030195192A1 (en) | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
EP1487796A4 (en) | 2002-03-28 | 2005-11-16 | Neurogen Corp | SUBSTITUTED BIARYLAMIDES AS MODULATORS OF THE C5A RECEPTOR |
EP1487798A4 (en) | 2002-03-28 | 2005-07-13 | Neurogen Corp | Substituted tetrahydroisoquinolines as C5A receptor modulators |
WO2003084524A1 (en) | 2002-03-29 | 2003-10-16 | Neurogen Corporation | Combination therapy for the treatment of conditions with pathogenic inflammatory components |
US20040014744A1 (en) | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
CA2494942A1 (en) * | 2002-08-08 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted benzimidazole compounds |
US7169775B2 (en) | 2002-08-21 | 2007-01-30 | Neurogen Corporation | Amino methyl imidazoles as C5a receptor modulators |
FR2846654A1 (fr) | 2002-11-05 | 2004-05-07 | Servier Lab | Nouveaux derives de la 2,3-dihydro-4(1h)-pyridinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
AU2003290605A1 (en) | 2002-11-05 | 2004-06-03 | The Regents Of The University Of Michigan | Compositions and methods for the diagnosis and treatment of sepsis |
AU2003291403A1 (en) | 2002-11-08 | 2004-06-03 | Neurogen Corporation | 3-substituted-6-aryl pyridined as ligands of c5a receptors |
AU2003902354A0 (en) | 2003-05-15 | 2003-05-29 | Harkin, Denis W. | Treatment of haemorrhagic shock |
BRPI0410630A (pt) | 2003-06-19 | 2006-06-13 | Pfizer Prod Inc | antagonista de nk1 |
WO2005007087A2 (en) | 2003-07-03 | 2005-01-27 | Neurogen Corporation | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators |
GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
NZ551603A (en) | 2004-06-24 | 2010-11-26 | Incyte Corp | N-substituted piperidines and their use as pharmaceuticals |
EP1621536A1 (en) * | 2004-07-27 | 2006-02-01 | Aventis Pharma S.A. | Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors |
US7635698B2 (en) | 2004-12-29 | 2009-12-22 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
BRPI0607756A2 (pt) | 2005-02-18 | 2010-05-18 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibição de dna girase bacteriana e/ou topoisomerase iv em um animal de sangue quente, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para preparar compostos ou sais farmaceuticamente aceitáveis dos mesmos |
WO2007035428A1 (en) | 2005-09-15 | 2007-03-29 | Bristol-Myers Squibb Company | Met kinase inhibitors |
WO2007051062A2 (en) | 2005-10-28 | 2007-05-03 | Chemocentryx, Inc. | Substituted dihydropyridines and methods of use |
CA2629935C (en) | 2005-11-24 | 2016-01-19 | Dompe S.P.A. | (r)-arylalkylamino derivatives and pharmaceutical compositions containing them |
DK2359834T5 (en) | 2006-03-15 | 2017-02-06 | Alexion Pharma Inc | Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor |
WO2008022060A2 (en) | 2006-08-14 | 2008-02-21 | Novartis Ag | Imidazo-pyridine derivatives for modulating protein kinase activity |
EP2077842A2 (en) | 2006-10-31 | 2009-07-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of an egfr antagonist for the treatment of glomerolonephritis |
EP2178835A1 (en) | 2007-06-29 | 2010-04-28 | Torrent Pharmaceuticals Ltd | Novel substituted piperidones as hsp inducers |
US9284297B2 (en) | 2008-08-11 | 2016-03-15 | President And Fellows Of Harvard College | Halofuginone analogs for inhibition of tRNA synthetases and uses thereof |
AU2009290137A1 (en) | 2008-09-03 | 2010-03-11 | Xenome Ltd | Libraries of peptide conjugates and methods for making them |
US20100074863A1 (en) | 2008-09-17 | 2010-03-25 | Yat Sun Or | Anti-infective pyrrolidine derivatives and analogs |
PT2894165T (pt) | 2008-11-10 | 2023-03-17 | Alexion Pharma Inc | Métodos e composições para o tratamento de distúrbios associados ao complemento |
SG172338A1 (en) | 2008-12-22 | 2011-07-28 | Chemocentryx Inc | C5ar antagonists |
US20110275639A1 (en) * | 2008-12-22 | 2011-11-10 | Chemocentryx, Inc. | C5aR ANTAGONISTS |
WO2011035143A2 (en) | 2009-09-17 | 2011-03-24 | The Regents Of The University Of Michigan | Methods and compositions for inhibiting rho-mediated diseases and conditions |
SI2585064T1 (sl) * | 2010-06-24 | 2017-08-31 | Chemocentryx, Inc. | Antagonisti C5AR |
CA2877526A1 (en) | 2012-06-20 | 2013-12-27 | Novartis Ag | Complement pathway modulators and uses thereof |
US20160060351A1 (en) | 2013-05-08 | 2016-03-03 | Novo Nordisk A/S | Use of C5AR Antagonists |
ES2926828T3 (es) | 2014-09-29 | 2022-10-28 | Chemocentryx Inc | Procesos e intermedios en la preparación de antagonistas de C5aR |
US20170202821A1 (en) | 2016-01-14 | 2017-07-20 | Chemocentryx, Inc. | Method of treating c3 glomerulopathy |
NZ747259A (en) | 2016-04-04 | 2022-11-25 | Chemocentryx Inc | Soluble c5ar antagonists |
KR20230124981A (ko) | 2020-12-21 | 2023-08-28 | 케모센트릭스, 인크. | C5a 억제제를 사용한 c3 사구체병증의 치료 |
-
2015
- 2015-09-28 ES ES20160995T patent/ES2926828T3/es active Active
- 2015-09-28 PL PL15845610T patent/PL3200791T3/pl unknown
- 2015-09-28 KR KR1020237035689A patent/KR20230149873A/ko active Application Filing
- 2015-09-28 CA CA3220371A patent/CA3220371A1/en active Pending
- 2015-09-28 BR BR112017006232-1A patent/BR112017006232B1/pt active IP Right Grant
- 2015-09-28 SG SG11201702185UA patent/SG11201702185UA/en unknown
- 2015-09-28 WO PCT/US2015/052697 patent/WO2016053890A1/en active Application Filing
- 2015-09-28 MX MX2017003789A patent/MX368492B/es active IP Right Grant
- 2015-09-28 CA CA2960733A patent/CA2960733C/en active Active
- 2015-09-28 CN CN202110432100.1A patent/CN113121415A/zh active Pending
- 2015-09-28 NZ NZ730123A patent/NZ730123A/en unknown
- 2015-09-28 NZ NZ767823A patent/NZ767823A/en unknown
- 2015-09-28 US US14/867,669 patent/US9745268B2/en active Active
- 2015-09-28 PT PT158456103T patent/PT3200791T/pt unknown
- 2015-09-28 DK DK15845610.3T patent/DK3200791T3/da active
- 2015-09-28 CN CN201580052937.6A patent/CN106999481B/zh active Active
- 2015-09-28 JP JP2017516679A patent/JP6898229B6/ja active Active
- 2015-09-28 ES ES15845610T patent/ES2802428T3/es active Active
- 2015-09-28 RU RU2017114960A patent/RU2712233C2/ru active
- 2015-09-28 EP EP15845610.3A patent/EP3200791B1/en active Active
- 2015-09-28 MA MA052308A patent/MA52308A/fr unknown
- 2015-09-28 AU AU2015324111A patent/AU2015324111B2/en active Active
- 2015-09-28 EP EP20160995.5A patent/EP3682879B1/en active Active
- 2015-09-28 KR KR1020177011789A patent/KR102593431B1/ko active IP Right Grant
-
2017
- 2017-03-09 IL IL251061A patent/IL251061B/en active IP Right Grant
- 2017-03-23 MX MX2019011911A patent/MX2019011911A/es unknown
- 2017-07-25 US US15/659,468 patent/US10266492B2/en active Active
-
2019
- 2019-03-21 US US16/360,195 patent/US10532982B2/en active Active
- 2019-12-06 US US16/706,296 patent/US20200354320A1/en not_active Abandoned
-
2021
- 2021-06-22 AU AU2021204209A patent/AU2021204209B2/en active Active
-
2022
- 2022-02-08 US US17/667,289 patent/US11845729B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019011911A (es) | Procesos e compuestos intermedios en la preparacion de antagonistas de c5ar. | |
ZA201806632B (en) | Soluble c5ar antagonists | |
PH12020550781A1 (en) | Anti-jagged1 antibodies and methods of use | |
PH12017500877A1 (en) | ANTI-CD79b ANTIBODIES AND METHODS OF USE | |
PH12016501894A1 (en) | Anti-ox40 antibodies and methods of use | |
MX2017005920A (es) | Anticuerpos anti-tim3 y metodos de uso. | |
IL250582B (en) | Compositions and methods for early screening of medical components | |
HK1250146A1 (zh) | 抗前-bcr拮抗劑和方法 | |
MX2016016233A (es) | Anticuerpos anti-lgr5 y sus usos. | |
HK1246288A1 (zh) | S1pr2拮抗劑及其用途 | |
PL3113774T3 (pl) | Kompozycje grapiprantu i sposoby ich zastosowania | |
IL251588A0 (en) | Methods and preparations for increasing the potency of antifungal agents | |
EP3140275A4 (en) | Bh4 antagonists and methods related thereto | |
ZA201807767B (en) | Angiotensin-1-receptor antagonists | |
PT3464324T (pt) | Antagonistas de recetores da angiotensina-1 | |
NZ744340A (en) | Anti-jagged1 antibodies and methods of use |